Generic Nasonex Launched
March 22, 2016 – The Generic Manufacturer, Apotex, announced the launch of its A-rated generic to Nasonex (mometasone furoate monohydrate) by Merck; a corticosteroid primarily used for the treatment of nasal symptoms associated with allergic rhinitis. Although nasal corticosteroids are in the process of transitioning from prescription to over-the-counter, plans and timing for Nasonex to convert from a prescription to an over-the-counter drug are currently unknown.
Other nasal corticosteroids including Flonase, Nasacort, and Rhinocort Aqua are already in the approval process. Dosage forms available for the newly launched generic include 50mcg of mometasone furoate in each 100 microliter nasal spray. The annual U.S. sale thus far, according to IMS Health is $955.5 million in the period of the most recent 12 months ending in January 2016.
Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval. Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.
*This is provided for information only. The reference to any medication above does not mean the medication is covered by your plan.